Bioengineered Skin and Soft Tissue Substitutes Policy number: I.202 Summary: The use of bioengineered skin and soft tissue substitutes is considered scientifically validated for the following indications: Breast reconstruction (including each of the following: AlloDerm , Cortiva [AlloMax], DermACELL, DermaMatrix, FlexHD , FlexHD Pliable) OR Diabetic lower extremity ulcers (AlloPatch a, Apligraf , Dermagraft , Integra Omnigraft Dermal Regeneration Matrix (also known as Omnigraft), and Integra Flowable Wound Matrix, mVASC , TheraSkin ) OR Venous insufficiency lower extremity ulcers (Apligraf , Oasis Wound Matrix) OR Dystrophic epidermolysis bullosa (OrCel (for the treatment of mitten-hand deformity when standard wound therapy has failed and when provided in accordance with the humanitarian device exemption [HDE] specifications of the U.S
those switched to placebo regained about 14% over the next year. Weight loss slows toward a plateau on a held dose rather than continuing indefinitely
Mol Metab (2021) 52:101325
SOURCE: The Associated Press , May 11, 2025 Copyright 2025 HealthDay
The process is quick, and pressure may be applied afterward to reduce any minor bleeding or discomfort